InnoSer offers excellent CRO services for drug discovery and preclinical drug development to battle a variety of diseases. Traditionally, InnoSer has a vast record of in vivo models in the fields of oncology, cardiovascular, polycystic kidney and infectious diseases and vaccines. In addition, InnoSer has consorted with several partners in both the academic and industrial field to generate patient-derived organoid based assays for the drug discovery and preclinical drug development chain. These assays, in contrast to traditional 2D cell systems, provide the optimum precis to effectively screen for compounds with the right therapeutic or optimum target specific profile. This allows our customers a higher reliability in preclinical testing, acceleration of their drug research and lowering the attrition rate. In addition, this services also the ability for a patient customized therapeutic setup.
InnoSer excels in combining both in vivo and in vitro disease modelling to offer one of the most reliable and innovative screening platforms known today. Our setup has received widespread support through several endowed project grants.